Mediclinic International (LON:MDC) was upgraded by research analysts at Jefferies Group to a “buy” rating in a research report issued on Thursday. The firm currently has a GBX 616 ($8.25) price objective on the stock, up from their prior price objective of GBX 550 ($7.37). Jefferies Group’s price objective would suggest a potential upside of 10.30% from the company’s previous close.

Other research analysts have also issued research reports about the company. Macquarie reduced their target price on Mediclinic International from GBX 760 ($10.18) to GBX 660 ($8.84) and set a “neutral” rating for the company in a report on Friday, October 20th. Citigroup reissued a “neutral” rating on shares of Mediclinic International in a report on Tuesday, November 21st. Credit Suisse Group cut their price objective on Mediclinic International from GBX 783 ($10.49) to GBX 630 ($8.44) and set a “neutral” rating for the company in a report on Monday, November 20th. Finally, J P Morgan Chase & Co lowered Mediclinic International to a “neutral” rating and cut their price objective for the stock from GBX 898 ($12.03) to GBX 733 ($9.82) in a report on Thursday, October 19th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of GBX 708.78 ($9.49).

Mediclinic International (LON:MDC) traded down GBX 7 ($0.09) during mid-day trading on Thursday, reaching GBX 558.50 ($7.48). The company’s stock had a trading volume of 2,517,817 shares, compared to its average volume of 2,410,000. Mediclinic International has a 1-year low of GBX 495.40 ($6.63) and a 1-year high of GBX 890.18 ($11.92).

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/02/mediclinic-international-mdc-rating-increased-to-buy-at-jefferies-group.html.

Mediclinic International Company Profile

Mediclinic International plc is an international private healthcare provider. The Company’s segments include Mediclinic Southern Africa, Mediclinic Switzerland, Mediclinic Middle East, United Kingdom and Corporate. It focuses on providing acute care and multidisciplinary healthcare services. It has interest in Spire Healthcare, a United Kingdom-based private healthcare company.

Analyst Recommendations for Mediclinic International (LON:MDC)

Receive News & Stock Ratings for Mediclinic International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediclinic International PLC and related stocks with our FREE daily email newsletter.